Get the Stockscreener App
0.00
100.00%
-0.157
Glycomimetics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
See More
Previous Close:
$0.157
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$11.00M
Revenue:
$1.16M
Net Income/Loss:
$-39.74M
P/E Ratio:
0.00
EPS:
-0.62
Net Cash Flow:
$-35.02M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
Name
Glycomimetics Inc
Sector
Industry
Phone
240-243-1201
Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare GLYC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.00 | 11.00M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Glycomimetics Inc Stock (GLYC) Latest News
What analysts say about GlycoMimetics Inc. stockUnbelievable profit margins - PrintWeekIndia
GlycoMimetics Inc. Stock Analysis and ForecastExplosive earnings growth - PrintWeekIndia
What drives GlycoMimetics Inc. stock priceLightning-fast growth - Autocar Professional
Is GlycoMimetics Inc. a good long term investmentRapid market gains - Autocar Professional
LifeSci Capital Initiates Coverage of GlycoMimetics (CBIO) with Outperform Recommendation - MSN
Why GlycoMimetics Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser
How GlycoMimetics Inc. stock performs during market volatility200 Percent Profit Outlook - Newser
What makes GlycoMimetics Inc. stock price move sharplySmart Money Trade Setups - Newser
Wedbush Initiates Crescent Biopharma at Outperform With $27 Price Target - MarketScreener
GlycoMimetics (NASDAQ:CBIO) Rating Increased to Strong-Buy at Lifesci Capital - Defense World
Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024 - MarketScreener
Crescent Biopharma Completes Merger with GlycoMimetics - TipRanks
Crescent Biopharma Completes Merger With GlycoMimetics - MarketScreener
Balance Sheet Dive: GlycoMimetics Inc (GLYC)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Crescent Biopharma Completes Closing of Merger with GlycoMimetic - GuruFocus
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million | CBIO Stock News - GuruFocus
Crescent Biopharma Completes Closing of Merger with - GlobeNewswire
Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced ... - Bluefield Daily Telegraph
Massive $200M Biotech Deal: Crescent Biopharma Secures Funding for Cancer Breakthrough Pipeline - Stock Titan
GlycoMimetics, Inc. Announces Board Changes - MarketScreener
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders - MarketScreener
GlycoMimetics Announces Chief Executive Officer Changes - MarketScreener
GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Sto - GuruFocus
GlycoMimetics (GLYC) Trading Halt Sparks Anticipation | GLYC Stock News - GuruFocus
GlycoMimetics (NASDAQ:GLYC) Shares to Reverse Split on Monday, June 16th - Defense World
Cantor Fitzgerald Comments on GlycoMimetics FY2026 Earnings - Defense World
Where Do Analysts Think The GlycoMimetics Inc (NASDAQ: GLYC) Is Going - Stocksregister
Glycomimetics Inc Stock (GLYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):